FDA
Boehringer's Zongertinib ReceivesFDA Priority Review for the Treatment of HER2 (ERBB2)- NSCLC
Boehringer Ingelheim Pharmaceuticals, Inc.
PR-02-25-NI-21Feb 20, 2025
Clinical Trials
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed CAR-T Product at ASCO GI 2025
EXUMA Biotechnology
PR-01-25-NI-26Feb 11, 2025
Agreement
Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
Glenmark Pharmaceuticals
PR-M08-18-NI-050Aug 13, 2018